ABC | Volume 111, Nº2, Agosto 2018

Diretrizes 3ª Diretriz Brasileira de Transplante Cardíaco Arq Bras Cardiol. 2018; 111(2):230-289 192. Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998;66(6):800-5. PMID: 9771846. 193. Garrett HE Jr, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant. 2005;24(9):1337-42. doi: 10.1016/j.healun.2004.09.003. 194. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12):1754-61. doi: 10.1097/ TP.0b013e318190af83. 195. Kfoury AG, Hammond ME, Snow GL, Drakos SG, Stehlik J, Fisher PW, et al. Cardiovascular mortality among heart tansplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody- mediated rejection. J Heart Lung Transplant. 2009;28(8):781-4. doi: 10.1016/j.healun.2009.04.035. 196. WuGW, Kobashigawa JA, FishbeinMC, Patel JK, KittlesonMM, Reed EF, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28(5):417-22. doi: 10.1016/j.healun.2009.01.015. 197. Dijke EI, Platt JL, Blair P, Clatworthy MR, Patel JK, Kfoury AG, et al. B cells in transplantation. J Heart Lung Transplant. 2016;35(6):704-10. doi: 10.1016/j.healun.2016.01.1232. 198. Heidt S, RoelenDL, Eijsink C, van Kooten C, Claas FH, Mulder A. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation. 2008;86(9):1292-300. doi: 10.1097/TP.0b013e3181874a36. 199. Bacal F, Sodré GL, Fernandes DA, Aiello VD, Stolf N, Bocchi E, et al. Methotrexate in acute persistent humoral rejection: an option for graft rescue. Ann Thorac Surg. 2003;76(2):607-10. PMID: 12902116. 200. Almuti K, Haythe J, Dwyer E, Itescu S, Burke E, Green P, et al. The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation. 2007;84(4):498-503. doi: 10.1097/01. tp.0000278094.41131.9f. 201. Barr ML, Baker CJ, Schenkel FA, McLaughlin SN, Stouch BC, Starnes VA, et al. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant. 2000;14(2):162-6. PMID: 10770423. 202. Wang H, Jiang J, Liu W, Kubelik D, Chen G, Gies D, et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibodycombinedwithcyclosporine.Transplantation.2005;79(9):1121- 7. PMID: 15880054. 203. Woodside KJ, Lick SD. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant. 2007;26(7):750-2. doi: 10.1016/j.healun.2007.04.012. 204. Byrne GW, Davies WR, Oi K, Rao VP, Teotia SS, Ricci D, et al. Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival. Transplantation. 2006;82(12):1787-91. doi: 10.1097/01. tp.0000251387.40499.0f. 205. Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am. 2010;24(2):273- 83. doi: 10.1016/j.idc.2010.01.005. 206. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994;170(3):644-52. PMID: 8077723. 207. Ljungman P, SnydmanD, BoeckhM. Transplant Infections. 4th ed. Boston: Springer International Publishing; 2016. p. 271-319. ISBN: 978-3-319- 28795-9. 208. Lima AM, Reis Filho EG, Reis CM. Study of dermatoses in kidney transplant patients. An Bras Dermatol. 2013;88(3):361-7. doi: http://dx.doi . org/10.1590/abd1806-4841.20131859. 209. Beek DV, Patel R, Daly RC. Central nervous system infection in heart transplant recipients. Arch Neurol. 2007;64(12):1715-20. doi: 10.1001/ archneur.64.12.noc70065. 210. Ramanan P, Razonable R. Cytomegalovirus Infections in solid organ transplantation: a review. Infect Chemother. 2013;45(3):260-71. doi: 10.3947/ic.2013.45.3.260. 211. Grossi P, Mohacsi P, Szabolcs Z. cytomegalovirus immunoglobulin after thoracic transplantation: an overview. Transplantation. 2016 Mar;100 Suppl 3:S1-4. doi: 10.1097/TP.0000000000001094. 212. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113(5):671-8. doi: 10.1161/CIRCULATIONAHA.105.580506. 213. Ganesh JS, Roger CA, Banner NR, Bonser RS, Steering Group of the UK Cardiothoracic Tarnsplant Audit. Development and validation of amodel to predict perioperative mortality following heart transplantation in the UK. J Heart Lung Transplant. 2004;23(2 Suppl):S118-9. 214. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931-40. doi: 10.1056/NEJMoa021744. 215. Shihab FS. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin Nephrol 1996;16(6):536-47. PMID: 9125798. 216. Naesens M, Kuyoers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin JAmSocNephrol.2009;4(2):481-508.doi:10.2215/CJN.04800908. 217. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant. 2006;6(4):671-9. doi: 10.1111/j.1600- 6143.2006.01248.x. 218. AngermannCE, Stork S, Costard-Jackle A, Dengler TJ, Siebert U, Tenderich G, et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients- -the IMPROVED multi-centre study. Eur Heart J. 2004;25(18):1626-34. doi: 10.1016/j.ehj.2004.06.032. 219. Bhatia SJ, Kirshembaum JM, Shemin RJ, Cohn LH, Collins JJ, Di Sesa VJ, et al. Time course of resolution of pulmonary hypertension and right ventricular remodelin after orthotopic cardiac transplantation. Circulation. 1987;76(4):819-26. PMID: 3308165. 220. Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, et al. International society for heart and lung transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29(7):717-27. doi: 10.1016/j.healun.2010.05.017. Erratum in: J Heart Lung Transplant. 2011;30(3):360. 221. Tsutsui H, Ziada KM, Schoenhagen P, Iyisoy A, Magyar WA, Crowe TD, et al. Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: results from a 5-year serial intravascular ultrasound study. Circulation. 2001;104(6):653-7. PMID: 11489770. 222. Derumeaux G, Redonnet M, Mouton-Schleifer D, Bessou JP, Cribier A, Saoudi N, et al. Dobutamine stress echocardiography in orthotopic heart transplant recipients. VACOMED Research Group. J Am Coll Cardiol. 1995;25(7):1665-72. PMID: 7759721. 223. Chirakarnjanakorn S, Starling RC, Popović ZB, Griffin BP, Desai MY. Dobutamine stress echocardiography during follow-up surveillance in heart transplant patients: Diagnostic accuracy and predictors of outcomes. J Heart Lung Transplant. 2015;34(5):710-7. doi: 10.1016/j. healun.2014.11.019. 224. Clerkin KJ, Farr MA, Restaino SW, Ali ZA, Mancini DM. Dobutamine stress echocardiography is inadequate to detect early cardiac allograft vasculopathy. JHeartLungTransplant.2016;35(8):1040-1.doi:10.1016/j. healun.2016.05.012. 225. Pollack A, Nazif T, Mancini D, Weisz G. Detection and imaging of cardiac allograft vasculopathy. JACCCardiovasc Imaging. 2013;6(5):613-23. doi: 10.1016/j.jcmg.2013.03.001. 226. Wever-Pinzon O, Romero J, Kelesidis I, Wever-Pinzon J, Manrique C, Budge D, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: ameta-analysis of prospective trials. J Am Coll Cardiol. 2014;63(19):1992-2004. doi: 10.1016/j. jacc.2014.01.071. 287